Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Abstract

BackgroundClear cell renal cell carcinoma (CCRCC) is a common urological neoplasm, and even though surgical resection is effective for localized CCRCC, the prognosis of metastatic CCRCC is poor. Currently, there is a paucity of recognized effective therapeutic protocols for metastatic CCRCC.Case presentationA 76-year-old Asian man underwent radical left nephrectomy for CCRCC 26 years ago; this patient visited our hospital with abdominal pain due to multiple abdominal metastases 24 years after the nephrectomy. After metastasectomy, he underwent targeted therapy combined with a programmed death receptor-1 (PD-1) inhibitor, and the current imaging results indicate remarkable tumor remission.ConclusionsMetachronous pancreatic metastasis from CCRCC after nephrectomy is rare, but clinicians and patients should not ignore this possibility. The combination of targeted therapy and immunotherapy can result in satisfactory outcomes in cases where metastatic CCRCC continues to progress despite metastasectomy and targeted therapy. The combination of local and systemic therapy can be an effective therapeutic protocol for metastatic CCRCC, but there is no consensus on suitable therapeutics.

Comprehensive analysis reveals the involvement of hsa_circ_0037858/miR-5000-3p/FMR1 axis in malignant metastasis of clear cell renal cell carcinoma

“…In this study, to explore the role and mechanism of circRNA in malignant metastasis of ccRCC, the potential datasets from the NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/) were included. The included datasets should meet the following criteria: (1) the included datasets should study the circRNA expression profile in ccRCC and/or normal tissues; (2) the datasets regarding cell lines should be excluded; (3) the datasets focusing on the circRNA expression in metastasis of ccRCC should also be included. At the end, only two datasets, consisting of GSE100186 and GSE137836, met the above selection criteria.…”

“…Renal cell carcinoma (RCC), originating from the renal epithelial cells, is a common malignant solid tumor of urinary system, accounting for 80-90% of all kidney malignancies [ 1 , 2 ]. RCC tumors are extremely heterogenous with multiple histological subtypes, among which clear cell renal cell carcinoma (ccRCC) is the most frequent one, making up nearly 70% of all kidney malignancies [ 3 ].…”